SOFOSBUVIR-VELPATASVIR 400-100

Velpatasvir and Sofosbuvir
$278.3270per EA

Strength

400; 100 mg/1; mg/1

NDC

72626270101

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

SOFOSBUVIR; VELPATASVIR

Approval Type

Authorized Generic (NDA)

FDA Application

NDA208341

On Market Since

11/14/2018

Pharmacological Classes

Breast Cancer Resistance Protein Inhibitors
Hepatitis C Virus NS5A Inhibitor
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Organic Anion Transporting Polypeptide 1B1 Inhibitors
Organic Anion Transporting Polypeptide 1B3 Inhibitors
Organic Anion Transporting Polypeptide 2B1 Inhibitors
P-Glycoprotein Inhibitors
RNA Replicase Inhibitors

Price History

1W

0.0%

1M

+0.1%

3M

+0.1%

6M

+0.0%

1Y

+0.3%

3Y

-0.0%

5Y

-1.6%

All

-1.6%